Ann: Security Class Reinstatement to Quotation- OPTOB, page-429

Hi primaus72,

I think @Bunter62 is absolutely right in pointing to the differences in BCVA at baseline being a significant contributor to the „better than MARINA“ results of P2b control: The lower BCVA at baseline, the higher the effect of anti-VEGF-A treatment.

A second effect stems from the exclusion of predominantly classic patients in MARINA as this subgroup got enrolled exclusively into ANCHOR. As predominantly classic patients respond best to anti-VEGF-A treatment, we have kind of an „underperformance“ at MARINA and kind of an „overperformance“ at ANCHOR.

Below you have a sample of all arms run in the pivotal trials ofLucentis, Eylea, Beovu, Vabysmo, Avastin and sozinibercept. According to this sample a „normal“ result for the P2b control arm would have been slightly less than +10 letters, maybe 9.8 letters which would equal to only 1.0 letters in „unexpected overperformance“ of P2b control left. A minor deviation only which I think should not be too much of concern.

On the other hand, the little graph shows the extreme deviation of the 2.0 mg sozinibercept arm in P2b compared to this sample of 25 anti-VEGF-A studies. And this is not even excluding RAP, nor limited to minimally classic and occult patients only as will be the case in topline readoiut in April 2025.

And I again agree with Bunter62, a 6 letter improvement ex RAP, ex predominantly classic is nothing that is totally out of reach. Actually all the opposite. And it remains without saying what this would mean to world of wAMD in general and OPT in particular.